<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DOXAPRAM HYDROCHLORIDE</span><br/>(dox'a-pram)<br/><span class="topboxtradename">Dopram<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">cerebral stimulant</span><br/><b>Prototype: </b>Caffeine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Short-acting analeptic capable of stimulating all levels of the cerebrospinal axis. Has minor effect on cortex. Respiratory
         stimulation by direct medullary action or possibly by indirect activation of peripheral chemoreceptors increases tidal volume
         and slightly increases respiratory rate.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Decreases Pco<sub>2</sub> and increases Po<sub>2</sub> by increasing alveolar ventilation; may elevate BP and pulse rate by stimulation of brain stem vasomotor area.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term adjunctive therapy to alleviate postanesthesia and drug-induced respiratory depression and to hasten arousal and
         return of pharyngeal and laryngeal reflexes. Also as a temporary measure (approximately 2 h) in hospitalized patients with
         COPD associated with acute respiratory insufficiency as an aid to prevent elevation of Paco<sub>2</sub> during administration of oxygen. (Not used with mechanical ventilation.)
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Neonatal apnea refractory to xanthine therapy.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Epilepsy and other convulsive disorders; of ventilatory mechanism due to muscle paresis, pulmonary fibrosis, flail chest,
         pneumothorax, airway obstruction, extreme dyspnea, or acute bronchial asthma; severe hypertension, coronary artery disease,
         uncompensated heart failure, CVA. Safe use during pregnancy (category B), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of bronchial asthma, COPD; cardiac disease, severe tachycardia, arrhythmias, hypertension; hyperthyroidism; pheochromocytoma;
         head injury, cerebral edema, increased intracranial pressure; peptic ulcer, patients undergoing gastric surgery; acute agitation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Postanesthesia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.51 mg/kg single injection not to exceed 1.5 mg/kg or 2 mg/kg total dose when repeated at 5 min intervals or 13
               mg/min infusion (max: 4 mg/kg or 300 mg, not to exceed 3 g/d)<br/><br/><span class="indicationtitle">Drug-Induced CNS Depression</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 12 mg/kg repeat in 5 min, then q12h until patient awakens [if relapse occurs, resume q12h injections (max:
               total dose 3 g), if no response after priming dose, may give 13 mg/min for up to 2 h until patient awakens]<br/><br/><span class="indicationtitle">Chronic Obstructive Pulmonary Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 12 mg/min for a max of 2 h (max: rate 3 mg/min)<br/><br/><span class="indicationtitle">Neonatal Apnea</span><br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 2.53 mg/kg followed by 1 mg/kg/h (titrate to max: 2.5 mg/kg/h)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>IV administration to neonates: Verify correct IV concentration and rate of infusion with physician. Generally do not use in
            newborns because doxapram contains benzyl alcohol.
         </li>
<li>Ensure adequacy of airway and oxygenation before initiation of doxapram therapy.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  <span class="methodtype">IV Infusion:</span> Dilute 250 mg (12.5 mL) in 250 mL of D5W or NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span>  Give undiluted over 5 min.  <span class="methodtype">IV Infusion:</span> Give at a rate of 13 mg/min, depending on patient response. Never exceed 3 mg/min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<b>Aminophylline,</b>
<b>ascorbic acid,</b>
<span class="classification">cephalosporins</span>, <b>carbenicillin,</b>
<b>dexamethasone,</b>
<b>diazepam,</b>
<b>digoxin,</b>
<b>dobutamine,</b>
<b>folic acid,</b>
<b>furosemide,</b>
<b>hydrocortisone,</b>
<b>ketamine,</b>
<b>methylprednisolone,</b>
<b>minocycline,</b>
<b>thiopental, </b>
<b>ticarcillin.</b>
<span class="incompattype">Y-site:</span>
<b>Clindamycin</b>. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, sneezing, apprehension, confusion, <span class="speceff-common">involuntary movements,</span> hyperactivity, paresthesias; feeling of warmth and burning, especially of genitalia and perineum; flushing, sweating, hyperpyrexia,
      headache, pilomotor erection, pruritus, muscle tremor, rigidity, convulsions, <span class="speceff-common">increased deep-tendon reflexes,</span> bilateral Babinski sign, <span class="speceff-common">carpopedal spasm,</span> pupillary dilation, mild delayed narcosis. <span class="typehead"> CV:</span>
<span class="speceff-common">Mild to moderate increase in BP, sinus tachycardia,</span> bradycardia, extrasystoles, lowered T waves, PVCs, chest pains, tightness in chest. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, salivation, sour taste. <span class="typehead">Urogenital:</span> Urinary retention, frequency, incontinence. <span class="typehead">Respiratory:</span> Dyspnea, tachypnea, cough, <span class="speceff-life">laryngospasm, bronchospasm</span>, hiccups, rebound hypoventilation, hypocapnia with tetany. <span class="typehead">Other:</span> Local skin irritation, thrombophlebitis with extravasation; decreased Hgb, Hct, and RBC count; elevated BUN; albuminuria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification">mao inhibitors</span>, <span class="classification">sympathomimetic agents</span> add to pressor effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span> 2040 s. <span class="typehead">Peak:</span> 12 min. <span class="typehead">Duration:</span> 512 min. <span class="typehead">Metabolism:</span> Rapidly metabolized. <span class="typehead">Elimination:</span> Excreted in urine as metabolites. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor IV site frequently. Extravasation or use of same IV site for prolonged periods can cause thrombophlebitis (see Appendix
            F) or tissue irritation.
         </li>
<li>Monitor carefully and observe accurately: BP, pulse, deep tendon reflexes, airway, and arterial blood gases. All are essential
            guides for determining minimum effective dosage and preventing overdosage. Make baseline determinations for comparison.
         </li>
<li>Lab tests: Draw arterial Po<sub>2</sub> and Pco<sub>2</sub> and O<sub>2</sub> saturation prior to both initiation of doxapram infusion and oxygen administration in patients with COPD, and then at least
            every 30 min during infusion. Infusion should not be administered for longer than 2 h.
         </li>
<li>Discontinue doxapram if arterial blood gases show evidence of deterioration and when mechanical ventilation is initiated.</li>
<li>Observe patient continuously during therapy and maintain vigilance until patient is fully alert (usually about 1 h) and protective
            pharyngeal and laryngeal reflexes are completely restored.
         </li>
<li>Notify physician immediately of any adverse effects. Be alert for early signs of toxicity: Tachycardia, muscle tremor, spasticity,
            hyperactive reflexes.
         </li>
<li>
            							Note: A mild to moderate increase in BP commonly occurs.
            						
         </li>
<li>Discontinue if sudden hypotension or dyspnea develops.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>